The Norwegian Radium Hospital, The Research Building
CCB congratulates Guro Elisabeth Lind with a one-year PI position for 2014.
We congratulate CCB co-director Ragnhild A. Lothe from the Department of Cancer Prevention at the Institute for Cancer Research with a new K.G. Jebsen Center for colorectal cancer research that recently has been appointed in strong competition with other outstanding scientific environments.
On Thursday, November 28th, at 13:15, Torfinn Nome will defend his thesis "Novel RNA variants in colorectal cancer identified by deep sequencing" for the PhD degree. Earlier the same day, at 10:15, his trial lecture will be given over the topic "Will deep sequencing and bioinformatics improve the success rate of translating cancer biomarkers to the clinic?". Nome has performed his PhD in the Genome Biology Group led by Rolf I. Skotheim at the Department of Cancer Prevention.
Beata Nadratowska-Wesolowska (photo) and colleagues from Antoni Wiedlocha’s group at the Centre for Cancer Biomedicine, Department of Biochemistry, Institute for Cancer Research, described a novel regulatory mechanism whereby activated RSK2 (p90 ribosomal S6 kinase2) directly interacts with and phosphorylates FGFR1, thereby modulating signaling through regulation of endocytosis.
In the July 27 issue of PLOS Biology (impact factor 12,69), Fergal O’Farrell and colleagues in Tor Erik Rusten’s group in the Centre for Cancer Biomedicine and Institute for Cancer Research published novel findings on the role of the Ret proto-oncogene orthologue in Drosophila with implications for understanding cancer development.
Cell density is an important factor when studying cells that are grown in culture. However, little is known about the molecular changes which occur during cell growth and how cellular responses are then modulated.
Professor Kirsten Sandvig at the Department of Biochemistry and Centre for Cancer Biomedicine at The Institute for Cancer Research, Oslo University Hospital (OUS), has received a grant of 30 million NOK over a 5 year period for the project “Biodegradable Nanoparticles in Cancer Diagnosis and Therapy”.
Researchers from Department of Cancer Prevention, Institute for Cancer Research and Centre for Cancer Biomedicine are involved in an international consortium on genetics of testicular germ cell tumours. The testicular cancer consortium, which is directed from National Cancer Institute and University of Pennsylvania, recently published two articles in Nature Genetics (Chung et al., May 2013) and Human Molecular Genetics (Schumacher et al., March 2013) respectively. Rolf Skotheim, the site responsible in Oslo, says that across all types of cancer, testicular cancer is now the type for which known susceptibility genes explain the largest fraction of the genetic risk.
Project group leader Alicia Llorente, working in the group of Kirsten Sandvig, has recently published the lipid composition of a prostate cancer cell line and of the exosomes released from these cells.
On Friday the 26th of April nine research prizes were awarded to scientists from Oslo University Hospital. Three CCB researchers were among the prize winners.
Department of Cancer Prevention receives funding from the Norwegian Research Council from the FORNY2020 and BIOTEK2021programmes for innovation projects on colorectal cancer. Development of prognostic and predictive markers for CRC is led by professor Ragnhild A. Lothe with Dr.s Rolf I. Skotheim, Guro E. Lind and professor Arild Nesbakken as active partners.
Drs Sigrid Marie Kraggerud, Christina Høi-Hansen and Sharmini Alagaratnam publish in Endrocrine Reviews, the highest ranked journal in the category of Endocrinology and metabolism with IF of 19.9.
Monday the 9th of April, Lind was invited to the radio program “Ekko” to talk about blood based testing for early detection of colorectal cancer.
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile selected innovation projects in the region by calling special attention to "The Innovator". For the month of March 2013, the honor goes to CCB's Co-director Ragnhild A. Lothe from the Department of Cancer Prevention at the Institute for Cancer Research, Oslo University Hospital.
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the month". For the month of March 2013, this honor goes to CCB's Professor Sverre Heim from the Section for Cancer Cytogenetics at the Institute for Medical Informatics, the Norwegian Radium Hospital.
Antoni Wiedlocha’s group has been awarded a grant for the project ”Highly cytotoxic FGF2-conjugates in targeted therapy for FGFR-expressing cancer” from the Polish-Norwegian Research Fund for a period of 3 years.
This project is a cooperation with Jacek Otlewski’s group at the University of Wroclaw, Poland. The in vivo part (experimental tumor models) of the project will be performed in collaboration with Skjalg Bruheim and Gunhild Mælandsmo from the Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital. The total project funding amounts to 1,000,000 Euro.
www.oncolex.org is a free, comprehensive online resource for cancer diagnostics, treatment and supportive care. It supplies health care providers worldwide with updated and detailed information on cancer care, sourced directly from acclaimed medical specialists at Oslo University Hospital and MD Anderson Cancer Center in Houston, Texas.
The research section of the Norwegian Cancer Society publishes popular scientific articles about successful research groups they support financially. The activities of Ragnhild A. Lothe's group at the Department of Cancer Prevention at the Institute for Cancer Research are now presented.
An article from the Wiedlocha group in CCB and the department of Biochemistry at the Institute for Cancer Research, entitled "ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser777 Inhibits Signaling" is published in the February 12th issue of the prestigious journal "Science signalling" (journal impact factor 7.5).
This work demonstrates a previously uncharacterized ERK1/2-mediated a negative feedback mechanism for the control of FGFR1 protecting cells from excessive FGFR1 signaling.
The number of incorrect cancer prognoses can be halved with computerised image analysis. In three years time, the method can be used on patients with bowel cancer, ovarian cancer and prostate cancer.
The first Apollon issue of 2013 features an interview with CCB's group leader, Professor Håvard Danielsen, Director of the Institute for Medical Informatics at Oslo University Hospital, and Professor Fritz Albregtsen from the Department of Informatics at Oslo University.